Non-genotoxic transplantation and in vivo selection through epitope editing.

Epitope editing of KIT combined with BCL11A disruption enables non-genotoxic, in vivo selection of gene-edited HSPCs, enhancing therapeutic potential for blood disorders.

• Why it matters: Current conditioning methods for HSPC transplantation involve genotoxic treatments that pose risks and limit broader application. Overcoming these barriers is crucial for safer, more effective therapies.
• What they did: The study used adenine base and prime editing to introduce amino acid mutations in KIT that block antibody binding without impairing function, alongside BCL11A disruption, and tested their enrichment under antibody pressure in vitro and in vivo.
• The result: Prolonged anti-KIT treatment enriched gene-edited HSPCs without clonal bias, enabling immune-based conditioning that maximizes niche clearance safely, paving the way for non-genotoxic transplantation strategies.